CorMedix Inc. (CRMD)
6.74
0.03 (0.45%)
At close: Mar 28, 2025, 3:59 PM
6.74
0.07%
After-hours: Mar 28, 2025, 06:51 PM EDT
0.45% (1D)
| Bid | 6.7 |
| Market Cap | 439M |
| Revenue (ttm) | 42.88M |
| Net Income (ttm) | -17.69M |
| EPS (ttm) | -0.3 |
| PE Ratio (ttm) | -22.45 |
| Forward PE | 21.18 |
| Analyst | Buy |
| Ask | 6.79 |
| Volume | 1,885,775 |
| Avg. Volume (20D) | 1,395,841 |
| Open | 6.62 |
| Previous Close | 6.71 |
| Day's Range | 6.31 - 6.77 |
| 52-Week Range | 3.61 - 13.85 |
| Beta | 1.53 |
About CRMD
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical setting...
Industry Biotechnology
Sector Healthcare
IPO Date May 13, 2010
Employees 64
Stock Exchange NASDAQ
Ticker Symbol CRMD
Website https://www.cormedix.com
Analyst Forecast
According to 7 analyst ratings, the average rating for CRMD stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 122.72% from the latest price.
Stock ForecastsEarnings Surprise
CorMedix has released their quartely earnings
on Mar 25, 2025:
Next Earnings Release
CorMedix Inc. is scheduled to release its earnings on May 8, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 days ago
-31.85%
CorMedix shares are trading lower. The company rep...
Unlock content with
Pro Subscription
3 weeks ago
+12.86%
CorMedix shares are trading higher after Leerink Partners initiated coverage on the stock with an Outperform rating on the stock and announced an $18 price target.
